How can immune checkpoint inhibitors differentiate themselves in the competitive Bladder cancer space?
Five PD-1/PD-L1 immune checkpoint inhibitors are approved for bladder cancer, but how are these therapies faring on the market? Find out how KOLs differentiate between the checkpoint inhibitors in this competitive and fast-evolving landscape and how they view the multitude of ongoing combination studies. Which checkpoint inhibitor do the KOLs think will dominate the market? A host of new targeted therapies are also in the pipeline including anti-VEGFR therapies (Eli Lilly’s Cyramza), FGFR inhibitors (Janssen/Astex’s erdafitinib, Bayer’s rogaratinib) and antibody-drug conjugates (Astellas/Seattle Genetics’ enfortumab vedotin). How will they impact future treatment pathways? What are the most important factors to ensure the successful uptake of other novel agents according to the experts?
Learn how KOLs see the market evolving, and how developers could differentiate their marketed and pipeline therapies in KOL Insight: Bladder Cancer. Twelve US and European KOLs provide their candid insights on eight marketed products, 12 Phase III pipeline programmes and early-stage mechanisms